Your session is about to expire
← Back to Search
Study Summary
This trial is trying to understand how the body processes Spironolactone and Hydrochlorothiazide after taking tablets made by two different companies, Viatris and Neolpharma. They are
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Frequently Asked Questions
What are the eligibility criteria for individuals to participate in this clinical study?
"To be considered eligible for this research study, potential participants must meet the criteria of being in good health and falling within the age range of 18 to 75. This trial has a capacity for a total enrollment of 40 individuals."
Is the clinical trial open to individuals who are above 80 years old?
"Eligible candidates for this scientific investigation must be between 18 and 75 years old. It is worth noting that there are currently 56 clinical trials available exclusively for individuals under the age of 18, as well as an additional 369 studies specifically targeting patients over the age of 65."
Are potential participants still able to enroll in this ongoing trial?
"As per the information found on clinicaltrials.gov, this particular trial is not seeking participants at present. The initial posting of the study was made on January 4th, 2024 and the most recent update occurred on January 11th, 2024. It's worth noting that while this specific trial is no longer recruiting patients, there are currently 760 other studies actively accepting participants."
What is the level of patient safety associated with Treatment B?
"Treatment B is rated as a 1 on the safety scale by our team at Power. This rating reflects the fact that it is currently in Phase 1 of the trial, indicating limited data supporting both its safety and efficacy."
Share this study with friends
Copy Link
Messenger